AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$TVTX

REED ELIZABETH E sold $2.3M of TVTX

REED ELIZABETH E (Chief Legal Officer and GC) sold 37,500 shares of Travere Therapeutics, Inc. (TVTX) at an average of $62.34 ($62.03–$65.31, $2.34M total) across 4 trades on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · REED ELIZABETH E
Published Sep 18, 2026, 1:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TVTX
Bearish
medium confidence
Mentioned
$TVTX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TVTXBearishLow
01

Why it matters

The disclosed sale may prompt short‑term selling pressure but is unlikely to move the stock significantly

02

Market read

Primary disclosure of a modest insider sale; low trading relevance

03

What to watch

Potential upcoming clinical data releases or partnership announcements could offset the negative signal

Relevance 5/10Novelty 4/10Timing: post‑market 2026‑09‑15

Background

SEC Form 4 filing discloses insider transactions for public companies

Company-level read

Ticker impact

$TVTXBearishMedium confidence
Context

Chief Legal Officer sold 37,500 shares for $2.34M via a 10b5‑1 plan on 2026‑09‑15

Expected impact

modest short‑term price dip

Evidence & confidence

Sale size is modest relative to holdings but indicates willingness to liquidate; market may view as slight bearish signal

Market effects

Sector

Minimal impact on the broader biotech sector; insider sales are routine

Regional

No regional effect beyond the company's share price

Global

Limited to investors tracking Travere Therapeutics

Counterpoint

What could challenge this read

The sale could be unrelated to fundamentals; the stock may still be undervalued

Key entities

  • Company
    Travere Therapeutics, Inc.

    Biopharmaceutical company listed on Nasdaq (TVTX)

  • Person
    Reed Elizabeth E.

    Chief Legal Officer and General Counsel of Travere

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TVTX insider trading history →

Related articles

OCT 23
$TVTXHighAI 8/10

At week 110, one kidney drug lowered an inflammation marker 45.4%; another raised it 8.7%.

Travere Therapeutics (TVTX) presented Phase 3 PROTECT Study data showing FILSPARI (sparsentan) reduced kidney inflammation biomarkers more than irbesartan in IgA nephropathy patients. At Week 110, FILSPARI decreased sCD163 (60.1%), BAFF (64.4%), C5b-9 (50.2%), and IL-6 (45.4%) compared to irbesartan. The study involved 404 patients, with 295 analyzed for biomarkers.

stocktitan.net2 min
SEP 30
$TVTXMed

Travere Therapeutics (TVTX) Secures FILSPARI Patent Extension, Is The Stock A Bargain?

Travere Therapeutics (TVTX) received a patent extension for FILSPARI, protecting its use in focal segmental glomerulosclerosis until October 2037. The company's stock has shown mixed performance, down 9.49% over 30 days but up 51.80% year-to-date. Analysts debate its valuation, with some seeing it as 19% undervalued at $59.99, while others note its higher P/S ratio compared to peers.

simplywall.st2 min